Bridgewater Advisors’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Bridgewater Advisors’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17,500	Closed	-$35K	–	239
2022 Q2	$35K	Hold	17,500	–	–	0.01%	223
2022 Q1	$41K	Hold	17,500	–	–	0.01%	238
2021 Q4	$81K	Sell	17,500 -22,000	-56%	-$137K	0.02%	242
2021 Q3	$301K	Buy	39,500 +7,000	+22%	+$59.4K	0.08%	189
2021 Q2	$315K	Buy	+32,500	New	+$259K	0.1%	179

Other funds holding SRNE

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bridgewater Advisors's SRNE Position: Q3 2022 in Review

Bridgewater Advisors sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2022, closing a stake of 17,500 shares — an estimated $35K sold.

Bridgewater Advisors first reported a position in SRNE in Q2 2021 and held it in 5 quarters. The position peaked at $315K in Q2 2021. 233 funds tracked by Wall St. Rank hold SRNE as of Q3 2022.

Bridgewater Advisors reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Bridgewater Advisors sold 17,500 Sorrento Therapeutics, Inc. shares in Q3 2022, an estimated $35K.
Bridgewater Advisors first reported a position in Sorrento Therapeutics, Inc. in Q2 2021 and held it in 5 quarters.
Bridgewater Advisors's Sorrento Therapeutics, Inc. position peaked at $315K in Q2 2021.
233 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2022.

Based on Bridgewater Advisors's 13F filing for Q3 2022, filed 28 Oct 2022.